Rocatinlimab

Drug

Related News

Kyowa Kirin and Kura start Japanese Phase II ziftomenib trial in relapsed or refractory AML

Apr 27, 2026

Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.

AAD 2026 and pipeline updates highlight new atopic dermatitis treatment data

Apr 21, 2026

Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.